Literature DB >> 11333558

[The COMBO project. Criteria and guidelines for combined therapy of type 2 diabetes. Consensus document (and II)].

A Goday Arno1, A Goday Arno1, F Alvarez Guisasola, J Díez Espino, I Fernández Fernández, D Tórtola Graner, D Acosta Delgado, M Aguilar Diosdado, J Herrera Pombo, L Felipe Pallardo.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11333558      PMCID： PMC7681722          DOI： 10.1016/s0212-6567(01)79381-x

Source DB:  PubMed          Journal:  Aten Primaria        ISSN： 0212-6567            Impact factor:   1.137


× No keyword cloud information.
  72 in total

1.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Authors:  R C Turner; C A Cull; V Frighi; R R Holman
Journal:  JAMA       Date:  1999-06-02       Impact factor: 56.272

2.  Repaglinide versus glyburide: a one-year comparison trial.

Authors:  T Marbury; W C Huang; P Strange; H Lebovitz
Journal:  Diabetes Res Clin Pract       Date:  1999-03       Impact factor: 5.602

3.  Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.

Authors:  Y Iwamoto; K Kosaka; T Kuzuya; Y Akanuma; Y Shigeta; T Kaneko
Journal:  Diabet Med       Date:  1996-04       Impact factor: 4.359

4.  Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.

Authors:  S Mäkimattila; K Nikkilä; H Yki-Järvinen
Journal:  Diabetologia       Date:  1999-04       Impact factor: 10.122

5.  Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

Authors:  S Schwartz; P Raskin; V Fonseca; J F Graveline
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

6.  Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.

Authors:  J B Buse; B Gumbiner; N P Mathias; D M Nelson; B W Faja; R W Whitcomb
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

7.  Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.

Authors:  E S Horton; F Whitehouse; M N Ghazzi; T C Venable; R W Whitcomb
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

8.  Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.

Authors:  R F Coniff; J A Shapiro; D Robbins; R Kleinfield; T B Seaton; P Beisswenger; J B McGill
Journal:  Diabetes Care       Date:  1995-06       Impact factor: 19.112

9.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

10.  Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

Authors:  D Giugliano; A Quatraro; G Consoli; A Minei; A Ceriello; N De Rosa; F D'Onofrio
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.